Effect of beclomethasone dipropionate/formoterol fumarate (BDP+FF) administered as a fixed pMDI combination on lung impedance and exhaled nitric oxide in comparison with the fixed combination of budesonide and formoterol fumarate (Symbicort Turbohaler). FLEX study (Foster fixed combination on Lung Impedance and Exhaled nitric oXide) A single-centre, randomized, double blind, double-dummy, two-way cross-over, repeated dose study.

Trial Profile

Effect of beclomethasone dipropionate/formoterol fumarate (BDP+FF) administered as a fixed pMDI combination on lung impedance and exhaled nitric oxide in comparison with the fixed combination of budesonide and formoterol fumarate (Symbicort Turbohaler). FLEX study (Foster fixed combination on Lung Impedance and Exhaled nitric oXide) A single-centre, randomized, double blind, double-dummy, two-way cross-over, repeated dose study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Beclometasone/formoterol; Budesonide/formoterol
  • Indications Asthma
  • Focus Biomarker; Therapeutic Use
  • Acronyms FLEX
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 03 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top